Anixa Biosciences granted ovarian cancer vaccine technology patent in Japan

Anixa Biosciences’ collaborator Cleveland Clinic has received a “Decision to Grant” notice from the Japan Patent Office for the patent application titled “Ovarian Cancer Vaccines.” The Ovarian Cancer Vaccines researchers demonstrated in pre-clinical studies that vaccination against the extracellular domain of anti-Mullerian hormone receptor II significantly inhibits tumor growth and enhances overall survival. The results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer. Anixa is the exclusive worldwide licensee for the vaccine technology from Cleveland Clinic, a nonprofit, multispecialty academic medical center.